Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Current perspectives on the treatment of rheumatic diseases with infliximab

Supplement

Autoantibodies in rheumatoid arthritis and their clinical significance

Günter Steiner* and Josef Smolen

Author Affiliations

Vienna General Hospital, University of Vienna, and Ludwig Boltzmann Institute for Rheumatology, Vienna, Austria

For all author emails, please log on.

Arthritis Res 2002, 4(Suppl 2):S1-S5  doi:10.1186/ar551

Published: 26 April 2002

Abstract

Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet been determined. The presence of rheumatoid factors is currently used as a marker for RA. However, rheumatoid factors have modest specificity (~70%) for the disease. In recent years, several newly characterized autoantibodies have become promising candidates as diagnostic indicators for RA. Antikeratin, anticitrullinated peptides, anti-RA33, anti-Sa, and anti-p68 autoantibodies have been shown to have >90% specificity for RA. These autoantibodies are reviewed and the potential role of the autoantibodies in the pathogenesis of RA is briefly discussed.

Keywords:
autoantibodies; diagnostic factors; pathogenesis; rheumatoid arthritis